<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="139593">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT01937182</url>
  </required_header>
  <id_info>
    <org_study_id>2013-002253-30</org_study_id>
    <nct_id>NCT01937182</nct_id>
  </id_info>
  <brief_title>The Efficacy of Citalopram Treatment in Acute Stroke</brief_title>
  <acronym>TALOS</acronym>
  <official_title>The Efficacy of Citalopram Treatment in Acute Stroke</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Aarhus</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Danish Council for Independent Research</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>University of Aarhus</source>
  <oversight_info>
    <authority>Denmark: Danish Health and Medicines Authority</authority>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Scientific evidence has indicated a positive effect of SSRI treatment (serotonin reuptake
      inhibitors) after stroke, beyond its known antidepressant effect. We wish to conduct a
      prospective, randomized, double blind, placebo controlled multi center study of the combined
      neuroprotective and antithrombotic effects of SSRI treatment after stroke.

      Hypotheses:

      SSRI treatment commenced in the acute phase of stroke (day 0-7) protects against new
      thromboembolic events and leads to better rehabilitation. 600 stroke patients will be
      randomized in a 1:1 ratio.

      The treatment and follow up period is 6 months. During these 6 months there will be 2
      clinical follow up visits, one telephone control and one visit to evaluate compliance
      regarding medication.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date>September 2013</start_date>
  <completion_date type="Anticipated">July 2021</completion_date>
  <primary_completion_date type="Anticipated">January 2016</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <study_design>Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment</study_design>
  <primary_outcome>
    <measure>Combined vascular death, TIA/re-stroke and STEMI</measure>
    <time_frame>6 months</time_frame>
    <safety_issue>No</safety_issue>
  </primary_outcome>
  <secondary_outcome>
    <measure>Death of any cause</measure>
    <time_frame>6 months</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Myocardial Infarction</measure>
    <time_frame>6 months</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Re-stroke</measure>
    <time_frame>6 months</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Bleeding complications</measure>
    <time_frame>6 months</time_frame>
    <safety_issue>Yes</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Combined vascular death</measure>
    <time_frame>6 months</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cognitive abilities</measure>
    <time_frame>6 months</time_frame>
    <safety_issue>No</safety_issue>
    <description>SDMT and MMSE tests are performed</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">600</enrollment>
  <condition>Stroke</condition>
  <arm_group>
    <arm_group_label>Selective Serotonin Reuptake Inhibitors</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Intervention Drug: Citalopram</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Intervention Drug: Placebo</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Citalopram</intervention_name>
    <description>Citalopram 10-40 mg per day administered orally</description>
    <arm_group_label>Selective Serotonin Reuptake Inhibitors</arm_group_label>
    <other_name>Selective Serotonin Reuptake Inhibitors</other_name>
    <other_name>SSRI</other_name>
    <other_name>SeropramÂ®</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>1/2-2 tablets per day with no intrinsic drug activity</description>
    <arm_group_label>Placebo</arm_group_label>
    <other_name>inactive drug</other_name>
    <other_name>inactive medicine</other_name>
    <other_name>inactive substance</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  First ever ischemic stroke

          -  Age 18 years or above

        Exclusion Criteria:

          -  Hemorrhagic stroke

          -  Dementia or other neurodegenerative disease

          -  Antidepressant treatment within 6 months of admission

          -  Acute need for antidepressant treatment

          -  Drug abuse or other conditions that may indicate noncompliant behavior

          -  Liver failure (increased liver enzyme levels up to or more than 2 times upper limit)

          -  Renal failure (GFR under 30)

          -  Hyponatremia (S-potassium below 130 mmol/l)

          -  Actively bleeding ulcer

          -  Fatal stroke or other severe co morbidity that markedly decreases expected life span

          -  Prolonged QT interval (QTc above 500 ms)

          -  Ongoing treatment with drugs known to prolong the QT interval
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Grethe Andersen, DSMc</last_name>
    <role>Study Chair</role>
    <affiliation>Aarhus University Hospital</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Kristian L Kraglund, M.D.</last_name>
    <role>Study Director</role>
    <affiliation>Aarhus University Hospital</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Boris Modrau, M.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Aalborg Universityhospital</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Helle Iversen, DSMc</last_name>
    <role>Principal Investigator</role>
    <affiliation>Glostrup University Hospital</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Kristian L Kraglund, M.D.</last_name>
    <phone>+4520739438</phone>
    <email>kriskrag@rm.dk</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Grethe Andersen, DMSc</last_name>
    <phone>+4578463294</phone>
    <email>greander@rm.dk</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Aalborg University Hospital, Department of Neurology</name>
      <address>
        <city>Aalborg</city>
        <zip>9100</zip>
        <country>Denmark</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Boris Modrau, M.D.</last_name>
      <phone>+45 98165927</phone>
      <email>boris.modrau@rn.dk</email>
    </contact>
    <investigator>
      <last_name>Boris Modrau, M.D.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Aarhus University Hospital, Department of Neurology</name>
      <address>
        <city>Aarhus</city>
        <zip>8000</zip>
        <country>Denmark</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Kristian L Kraglund, M.D.</last_name>
      <phone>+45 20739438</phone>
      <email>kriskrag@rm.dk</email>
    </contact>
    <contact_backup>
      <last_name>Grethe Andersen, DSMc</last_name>
      <phone>+45 78463294</phone>
      <email>greander@rm.dk</email>
    </contact_backup>
    <investigator>
      <last_name>Kristian L Kraglund, M.D.</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Grethe Andersen, DSMc</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Janne K Mortensen, M.D.</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Glostrup University Hospital, Department of Neurology</name>
      <address>
        <city>Glostrup</city>
        <zip>2600</zip>
        <country>Denmark</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Helle Iversen, DSMc</last_name>
      <phone>+45 38633400</phone>
      <email>heiv@regionh.dk</email>
    </contact>
    <investigator>
      <last_name>Helle Iversen, DSMc</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Sofie A Simonsen, M.D.</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Denmark</country>
  </location_countries>
  <verification_date>September 2013</verification_date>
  <lastchanged_date>April 2, 2014</lastchanged_date>
  <firstreceived_date>September 3, 2013</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Stroke</keyword>
  <keyword>SSRI</keyword>
  <keyword>CT (computerized tomography)</keyword>
  <keyword>MRI (Magnetic Resonance Imaging)</keyword>
  <is_fda_regulated>No</is_fda_regulated>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Stroke</mesh_term>
    <mesh_term>Cerebral Infarction</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Citalopram</mesh_term>
    <mesh_term>Serotonin Uptake Inhibitors</mesh_term>
    <mesh_term>Dexetimide</mesh_term>
    <mesh_term>Serotonin</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
